One of the challenges manufacturers face is ensuring sufficient evidence to support not only product approval, but also reimbursement and market adoption. This is particularly relevant for early stage biotech companies that tend to focus on regulatory submission and not on how the product will be reimbursed and ultimately adopted. Payers and providers are scrutinizing reimbursement and adoption decisions, insisting that products be linked to clear-cut clinical and/or cost benefits. In light of this, investors must ensure that assets demonstrate differentiated economic and clinical value.
This session will discuss how evolving evidentiary requirements factor into investment decisions and how biotech companies can demonstrate and communicate the value of their assets to investors. The panelists will offer critical insights into what’s driving their decisions now, as well as guidance on where evidence generation and valuation is going.

Ability Level: All

Session ID: 21003